ABSTRACT
Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus (DM) and the dysfunction of Schwann cells plays an important role in the pathogenesis of DPN. Thioredoxin-interacting protein (TXNIP) is known as an inhibitor of thioredoxin and associated with oxidative stress and inflammation. However, whether TXNIP is involved in dysfunction of Schwann cells of DPN and the exact mechanism is still not known. In this study, we first reported that TXNIP expression was significantly increased in the sciatic nerves of diabetic mice, accompanied by abnormal electrophysiological indexes and myelin sheath structure. Similarly, in vitro cultured Schwann cells TXNIP was evidently enhanced by high glucose stimulation. Again, the function experiment found that knockdown of TXNIP in high glucose-treated RSC96 cells led to a 4.12 times increase of LC3-II/LC3-I ratio and a 25.94% decrease of cleaved caspase 3/total caspase 3 ratio. Then, DNA methyltransferase (DNMT) inhibitor 5-Aza has been reported to benefit Schwann cell in DPN, and here 5-Aza treatment reduced TXNIP protein expression, improved autophagy and inhibited apoptosis in high glucose-treated RSC96 cells and the sciatic nerves of diabetic mice. Furthermore, DNMT1 and DNMT3a upregulation were found to be involved in TXNIP overexpression in high glucose-stimulated RSC96 cells. Silencing of DNMT1 and DNMT3a effectively reversed high glucose-enhanced TXNIP. Moreover, high glucose-inhibited PI3K/Akt pathway led to DNMT1, DNMT3a, and TXNIP upregulation in RSC96 cells. Knockdown of DNMT1 and DNMT3a prevented PI3K/Akt pathway inhibition-caused TXNIP upregulation in RSC96 cells. Finally, in vivo knockout of TXNIP improved nerve conduction function, increased autophagosome and LC3 expression, and decreased cleaved Caspase 3 and Bax expression in diabetic mice. Taken together, PI3K/Akt pathway inhibition mediated high glucose-induced DNMT1 and DNMT3a overexpression, leading to cell autophagy inhibition and apoptosis via TXNIP protein upregulation in Schwann cells of DPN.
Subject(s)
Carrier Proteins/metabolism , Cell Cycle Proteins/metabolism , DNA (Cytosine-5-)-Methyltransferase 1/metabolism , DNA (Cytosine-5-)-Methyltransferases/metabolism , Diabetic Neuropathies/enzymology , Phosphatidylinositol 3-Kinase/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Schwann Cells/enzymology , Sciatic Nerve/enzymology , Thioredoxins/metabolism , Animals , Apoptosis , Apoptosis Regulatory Proteins/metabolism , Autophagy , Autophagy-Related Proteins/metabolism , Blood Glucose/metabolism , Carrier Proteins/genetics , Cell Cycle Proteins/genetics , Cell Line , DNA (Cytosine-5-)-Methyltransferase 1/genetics , DNA (Cytosine-5-)-Methyltransferases/genetics , DNA Methyltransferase 3A , Diabetic Neuropathies/genetics , Diabetic Neuropathies/pathology , Disease Models, Animal , Humans , Male , Mice, Inbred C57BL , Mice, Knockout , Rats , Schwann Cells/pathology , Sciatic Nerve/pathology , Signal Transduction , Thioredoxins/geneticsABSTRACT
High glucose (HG)-induced nucleotide-binding and oligomerization (NACHT) domain, leucine-rich repeat (LRR), and pyrin domain (PYD)-containing protein 3 (NLRP3) inflammasome activation leads to diabetic neuropathic pain. We recently showed that salidroside could suppress NLRP3 inflammasome activation in hepatocytes exposed to HG. The aim of this study was to evaluate the analgesic effect of salidroside on diabetic rats and to explore its underlying mechanisms. Rat models with diabetic neuropathic pain were induced by high-fat diet feeding combined with low dose streptozotocin injections. Doses of salidroside at 50 and 100 mg.kg-1.day-1 were administered by gavage to diabetic rats for 6 weeks. Mechanical allodynia test, thermal hyperalgesia test and biochemical analysis were performed to evaluate therapeutic effects. Primary dorsal root ganglion (DRG) cells exposed to HG at 45 mM were used to further study the effects of salidroside on the AMP-activated protein kinase (AMPK)-NLRP3 inflammasome axis and insulin sensitivity in vitro. Salidroside administration improved hyperglycemia, ameliorated insulin resistance, and alleviated neuropathic pain in diabetic rats. Moreover, salidroside induced AMPK activation and suppressed NLRP3 inflammasome activation in the DRGs of diabetic rats. In addition, salidroside treatment relieved oxidative stress, improved insulin sensitivity and regulated the AMPK-NLRP3 inflammasome axis in HG-treated DRGs in vitro. Furthermore, AMPK inhibition in vivo or AMPK silencing in vitro abolished the beneficial effects of salidroside on diabetic neuropathic pain. Together, these results indicate that salidroside alleviates diabetic neuropathic pain through its regulation of the AMPK-NLRP3 inflammasome axis in DRGs.
Subject(s)
AMP-Activated Protein Kinases/metabolism , Analgesics/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Diabetic Neuropathies/prevention & control , Ganglia, Spinal/drug effects , Glucosides/pharmacology , Hypoglycemic Agents/pharmacology , Inflammasomes/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Neuralgia/prevention & control , Phenols/pharmacology , Animals , Blood Glucose/drug effects , Blood Glucose/metabolism , Cells, Cultured , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/etiology , Diabetic Neuropathies/physiopathology , Ganglia, Spinal/enzymology , Ganglia, Spinal/physiopathology , Insulin Resistance , Male , Neuralgia/enzymology , Neuralgia/etiology , Neuralgia/physiopathology , Oxidative Stress/drug effects , Pain Threshold/drug effects , Rats, Sprague-Dawley , Signal TransductionABSTRACT
Bupivacaine (Bup) has a certain research basis in pain-related diseases, but it has not been studied in painful diabetic neuropathy. In this study, we investigated the role of Bupivacaine in painful diabetic neuropathy. Mouse model with painful diabetic neuropathy was established, and then treated with different concentrations of Bupivacaine. The blood glucose level in the tail vein and the changes in body weight was measured. The mechanical allodynia, thermal hyperalgesia and thermal allodynia was assessed by pain behavioral tests. Microglia were treated with high glucose (HG) and different concentrations of Bupivacaine. The levels of inflammatory cytokines were detected by using Enzyme-linked immunosorbent assays. Dual luciferase reporter assay explored the relationship between miR-23a and phosphodiesterase 4 B (PDE4B). The results displayed that Bupivacaine ameliorated the mechanical allodynia, thermal hyperalgesia, and thermal allodynia in mice with painful diabetic neuropathy, and is more effective at low concentration. Moreover, low concentration of Bupivacaine inhibited inflammation and promoted miR-23a expression in mice with painful diabetic neuropathy and in microglia induced by HIGH GLUCOSE. Overexpression of miR-23a reduced the levels of inflammatory cytokines by down-regulating PDE4B expression. Knockdown of miR-23a reversed the inhibition effect of Bupivacaine on microglial inflammation. These results revealed that low concentration of Bupivacaine inhibited microglial inflammation through down-regulating PDE4B via miR-23a, thereby attenuated painful diabetic neuropathy.
Subject(s)
Anesthetics, Local/pharmacology , Bupivacaine/pharmacology , Cerebral Cortex/drug effects , Cyclic Nucleotide Phosphodiesterases, Type 4/metabolism , Diabetic Neuropathies/prevention & control , Hyperalgesia/prevention & control , MicroRNAs/metabolism , Microglia/drug effects , Pain Threshold/drug effects , Animals , Behavior, Animal/drug effects , Blood Glucose/metabolism , Cerebral Cortex/metabolism , Cerebral Cortex/physiopathology , Cytokines/metabolism , Diabetes Mellitus, Experimental/complications , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/etiology , Diabetic Neuropathies/physiopathology , Hyperalgesia/enzymology , Hyperalgesia/etiology , Hyperalgesia/physiopathology , Inflammation Mediators/metabolism , Male , Mice, Inbred C57BL , MicroRNAs/genetics , Microglia/enzymology , Signal Transduction , Spinal Cord/drug effects , Spinal Cord/enzymology , Spinal Cord/physiopathology , StreptozocinABSTRACT
The human body has a mechanism for balancing the generation and neutralization of reactive oxygen species. The body is exposed to many agents that are responsible for the generation of reactive oxygen/nitrogen species, which leads to disruption of the balance between generation of these species and oxidative stress defence mechanisms. Diabetes is a chronic pathological condition associated with prolonged hyperglycaemia. Prolonged elevation of level of glucose in the blood leads to the generation of reactive oxygen species. This generation of reactive oxygen species is responsible for the development of diabetic vasculopathy, which includes micro- and macrovascular diabetic complications. Nicotinamide adenine dinucleotide phosphate oxidase (NOX) is a membrane-bound enzyme responsible for the development of reactive oxygen species in hyperglycaemia. Phosphorylation of the cytosolic components of NOX, such as p47phox, p67phox, and RAC-1, in hyperglycaemia is one of the important causes of conversion of oxygen to reactive oxygen. Overexpression of NOX in pathological conditions is associated with activation of aldose reductase, advanced glycation end products, protein kinase C and the hexosamine pathway. In addition, NOX also promotes the activation of inflammatory cytokines, such as TGF-ß, TNF-α, NF-kß, IL-6, and IL-18, the activation of endothelial growth factors, such as VEGF and FGF, hyperlipidaemia, and the deposition of collagen. Thus, overexpression of NOX is linked to the development of diabetic complications. The present review focuses on the role of NOX, its associated pathways, and various NOX inhibitors in the management and treatment of diabetic complications, such as diabetic nephropathy, retinopathy, neuropathy and cardiomyopathy.
Subject(s)
Diabetic Cardiomyopathies/enzymology , Diabetic Nephropathies/enzymology , Diabetic Neuropathies/enzymology , Diabetic Retinopathy/enzymology , NADPH Oxidases/metabolism , Reactive Oxygen Species/metabolism , Animals , Diabetic Cardiomyopathies/drug therapy , Diabetic Nephropathies/drug therapy , Diabetic Neuropathies/drug therapy , Diabetic Retinopathy/drug therapy , Enzyme Inhibitors/therapeutic use , Humans , NADPH Oxidases/antagonists & inhibitors , Oxidative Stress , Signal TransductionABSTRACT
BACKGROUND: The clinical efficacy of electroacupuncture in treating diabetic peripheral neuropathy (DPN) is significant, but the underlying mechanism of action is not clear. Considering that glucose-regulated protein 78 (GRP78) and caspase-12 are major proteins participating in cell apoptosis, we investigated the effects of "adjusting internal organs and dredging channel" electroacupuncture therapy on GRP78 and caspase-12 levels in streptozotocin (STZ)-diabetic rats to elucidate the mechanism of action. METHODS: Rats were first divided into two groups: one group was rendered diabetic with a single injection of 50 mg/kg STZ, whereas the other normal control group was injected with an equivalent volume of citrate buffer. The STZ-diabetic rats were randomly divided into three groups: model control and electroacupuncture- and mecobalamin-treated groups. After 12 weeks treatment, the therapeutic efficacy of electroacupuncture was assessed using sciatic nerves isolated from rats. In the electroacupuncture group, rats were treated by electroacupuncture for 20 minutes once daily for 6 days each week, with 1 day off, for 12 consecutive weeks. The selected acupressure points include bilateral acupressure points of BL13 (Fehu), BL20 (Pishu), BL23 (Shenshu), LI4 (Hegu), LR3 (faichong), ST36 (Zusanli), and SP6 (Sanyiniiao). Acupressure points were stimulated using a HuaTuo SDZ-V Electric Acupuncture Therapy Apparatus. The acupressure points of BL13 and BL23, as well as SP6 and LR3, were connected on the same side with a dilatational wave of 3 Hz (frequency ratio of 1 : 5) to stimulate the parts of the body to the extent that could be tolerated by the rat. As for the mecobalamin-treated groups, mecobalamin was administrated to rats intragastrically at a dose of 20 mg/kg once daily for 12 consecutive weeks. Immunofluorescence and western blot analysis were used to determine GRP78 and caspase-12 levels in sciatic nerves. In addition, cell apoptosis in sciatic nerves was determined using the terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-labeling (TUNEL) assay. RESULTS: Electroacupuncture markedly reduced the pathological injury to sciatic nerves in STZ-diabetic rats. Moreover, electroacupuncture significantly downregulated GRP78 and caspase-12 and reduced cell apoptosis of sciatic nerves in DPN rats. CONCLUSIONS: Electroacupuncture improved DPN by downregulating GRP78 and caspase-12 and reducing cell apoptosis of sciatic nerves in STZ-diabetic rats, and further inhibited the occurrence of endoplasmic reticulum stress, thus preventing sciatic nerve injuries.
Subject(s)
Caspase 12/metabolism , Diabetes Mellitus, Experimental/therapy , Diabetic Neuropathies/prevention & control , Electroacupuncture , Heat-Shock Proteins/metabolism , Sciatic Nerve/enzymology , Streptozocin , Acupuncture Points , Animals , Apoptosis , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/enzymology , Diabetes Mellitus, Experimental/pathology , Diabetic Neuropathies/chemically induced , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/pathology , Down-Regulation , Male , Rats, Sprague-Dawley , Sciatic Nerve/ultrastructure , Signal TransductionABSTRACT
Cardiac autonomic neuropathy is a neglected diabetic chronic complication for which genetic predictors are rarely reported. Oxidative stress is implicated in the pathogenesis of microvascular complications, and glutathione peroxidase 4 is involved in the detoxification of peroxides and of reactive oxygen species. Thus, the association of a functional variant in the gene encoding glutathione peroxidase 4 (rs713041) with this diabetic complication was investigated in 341 individuals with type 1 diabetes evaluated for cardiac autonomic neuropathy status (61.7% women, 34 [27-42] years old; diabetes duration: 21 [15-27] years; HbA1c: 8.3% [7.4-9.4]; as median [interquartile interval]). Cardiac autonomic neuropathy was present in 29% of the participants. There was an inverse association of the minor T allele of rs713041 with cardiac autonomic neuropathy (odds ratio = 0.39; 95% confidence interval = 0.17-0.90; p = 0.0271) after adjustment for potential confounders. The functional glutathione peroxidase 4 variant rs713041 modulated the risk for cardiac autonomic neuropathy in the studied population with type 1 diabetes.
Subject(s)
Autonomic Nervous System/physiopathology , Cardiovascular System/physiopathology , Diabetes Mellitus, Type 1/genetics , Diabetic Neuropathies/genetics , Glutathione Peroxidase/genetics , Polymorphism, Single Nucleotide , Adult , Cross-Sectional Studies , Diabetes Mellitus, Type 1/diagnosis , Diabetes Mellitus, Type 1/enzymology , Diabetic Neuropathies/diagnosis , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/physiopathology , Female , Gene Frequency , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Male , Phenotype , Phospholipid Hydroperoxide Glutathione Peroxidase , Risk Assessment , Risk FactorsABSTRACT
Diabetic neuropathy (DN) is one of most disabling disorder complicating diabetes mellites (DM), which affects more than 50% of the all diabetic patients during the disease course. Duloxetine (DX) is one of the first-line medication that approved by FDA for management of DN, nevertheless, it is too costly and has many adverse effects. Recently, phloretin (PH) exhibited powerful euglycemic, antihyperlipidemic, antioxidant, and anti-inflammatory activities. Therefore, we investigated the in vivo possible antineuropathic activity of phloretin, besides, its modulating effects on duloxetine potency, in a rat model of DN. Twelve-week-old male Wistar rats received a single intraperitoneal injection of 55â¯mg/kg STZ to induce DM. Either DX (30 or 15â¯mg/kg dissolved in distilled water), PH (50 0r 25â¯mg/kg dissolved in 0.5% DMSO) or a combination of 15â¯mg/kg DX and 25â¯mg/kg PH, used daily orally for 4 weeks to treat DN, starting from the end of the 4th week of DM development, when DN confirmed. Our finding showed that both DX and PH dose-dependently improved behavioral parameters (with the superiority of DX), sciatic nerve tissue antioxidant state, and suppressed tissue inflammatory cytokine, besides, they abrogated the tissue histopathological changes (with the superiority of PH). Moreover, DX augmented the DM metabolic disturbance and hepatic dysfunction, however, PH effectively amended these disorders. Furthermore, the low-dose combination of both, had the merits of both medications, with the alleviation of their disadvantages. Therefore, phloretin could be a promising agent in the management of DN either alone or in combination with duloxetine.
Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Diabetic Neuropathies/drug therapy , Duloxetine Hydrochloride/therapeutic use , Phloretin/therapeutic use , Animals , Behavior, Animal , Blood Glucose/metabolism , Capillaries/pathology , Cold Temperature , Cytokines/metabolism , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/enzymology , Diabetic Neuropathies/blood , Diabetic Neuropathies/complications , Diabetic Neuropathies/enzymology , Duloxetine Hydrochloride/pharmacology , Glycated Hemoglobin/metabolism , Hyperalgesia/blood , Hyperalgesia/complications , Hyperalgesia/drug therapy , Hyperalgesia/enzymology , Lipids/blood , Male , Oxidative Stress/drug effects , Phloretin/pharmacology , Rats, Wistar , Sciatic Nerve/drug effects , Sciatic Nerve/pathology , Sciatic Nerve/ultrastructure , Streptozocin , Transaminases/metabolismABSTRACT
INTRODUCTION: Uncontrolled chronic hyperglycemia in diabetic patients could result in various complications, including neurotoxicity. Urtica dioica L. (UD) is known for its hypoglycemic and antioxidant effects. In this study, we evaluated the efficacy of UD and pioglitazone (PIO) in reduction of neurotoxicity and oxidative stress in streptozocin-induced diabetic mice. MATERIALS AND METHODS: Male mice were divided into seven groups: control, diabetic, dimethyl sulfoxide-treated control, PIO-treated, UD-treated, UD-PIO-treated, and vitamin E-treated. For induction of diabetes, streptozocin was injected in a single dose (65 mg/kg, i.p.). All treatments were performed for 5 weeks. Neurotoxicity was evaluated through hot plate and formalin test. Then, animals were killed, brain tissue was separated and the mitochondrial fraction was isolated with different centrifuge technique. Also, oxidative stress markers (reactive oxygen species, lipid peroxidation, protein carbonyl, glutathione) were measured in brain. Mitochondrial function was evaluated by MTT test in brain isolated mitochondria. RESULTS: Elevation of oxidative stress markers and mitochondrial damage were observed in diabetic mice compared to control group. Administration of PIO and UD ameliorated the oxidative stress and mitochondrial damage (p < 0.05) in diabetic mice. Also increase in pain score was shown in diabetic mice that treatment with UD and PIO diminished elevation of pain score in diabetic mice. Interestingly, simultaneous administration of PIO and UD showed synergism effect in attenuation of oxidative stress and hyperglycemia. CONCLUSION: UD showed a therapeutic potential for the attenuation of oxidative stress and diabetes-induced hyperglycemia that can be considered as co-treatment in treatment of diabetic neurotoxicity.
Subject(s)
Diabetic Neuropathies/prevention & control , Hypoglycemic Agents/therapeutic use , Mitochondria/drug effects , Neuroprotective Agents/therapeutic use , Plant Components, Aerial/chemistry , Plant Extracts/therapeutic use , Urtica dioica/chemistry , Animals , Antioxidants/isolation & purification , Antioxidants/therapeutic use , Biomarkers/metabolism , Brain/drug effects , Brain/enzymology , Brain/metabolism , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/drug therapy , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/metabolism , Drug Synergism , Drug Therapy, Combination , Hypoglycemic Agents/isolation & purification , Iran , Lipid Peroxidation/drug effects , Male , Mice , Mitochondria/enzymology , Mitochondria/metabolism , Neurons/drug effects , Neurons/enzymology , Neurons/metabolism , Neuroprotective Agents/isolation & purification , Oxidative Stress/drug effects , Pioglitazone , Plant Components, Aerial/growth & development , Plant Extracts/isolation & purification , Protein Carbonylation/drug effects , Thiazolidinediones/therapeutic use , Urtica dioica/growth & developmentABSTRACT
Diabetic peripheral neuropathy (DPN) is one of the major complications associated with diabetes. It is characterized by the degeneration of the myelin sheath around axons, referred to as demyelination. Such demyelinations are often caused by reduced lipid component of the myelin sheath. Since, lipoprotein lipase (LPL) provides the lipid for myelin sheath by hydrolysing the triglyceride rich lipoproteins, and also helps in the uptake of lipids by the Schwann cells (SCs) for its utilization, LPL is considered as the important factor in the regeneration of myelin sheath during diabetic neuropathy. Earlier reports from our laboratory have provided the insights of insulin and its receptor in SCs during diabetic neuropathy. In order to evaluate the long term effect of insulin on lipid metabolism during diabetic neuropathy, in this study, we analyzed the expression of LPL in SCs under normal, high glucose and insulin treated conditions. A decrease in the expression of LPL was observed in SCs of high glucose condition and it was reversed upon insulin treatment. Histochemical observations of sciatic nerve of insulin treated neuropathy subjects showed the improved nerve morphology, signifying the importance of insulin in restoring the pathophysiology of diabetic neuropathy.
Subject(s)
Diabetes Mellitus, Experimental/complications , Diabetic Neuropathies/enzymology , Gene Expression Regulation, Enzymologic/drug effects , Glucose/pharmacology , Insulin/pharmacology , Lipoprotein Lipase/metabolism , Schwann Cells/enzymology , Animals , Diabetes Mellitus, Experimental/drug therapy , Diabetic Neuropathies/drug therapy , Diabetic Neuropathies/etiology , Hypoglycemic Agents/pharmacology , Rats , Rats, Wistar , Schwann Cells/drug effects , Schwann Cells/pathology , Sciatic Nerve/drug effects , Sciatic Nerve/enzymology , Sciatic Nerve/pathology , Sweetening Agents/pharmacology , Up-RegulationABSTRACT
BACKGROUND: Methylene-tetrahydrofolate reductase (MTHFR) gene variant may play an important role in the pathophysiology of diabetes and its complications due to its influence on plasma homocysteine levels and also its effect on scavenging peroxynitrite radicals. Diabetic peripheral neuropathy (DPN) is one of the most common diabetic chronic complications. The aim of this study was to investigate the relationship between diabetic neuropathy and MTHFR gene C677T and 1298A /C polymorphisms. METHOD: Patients with type 2 diabetes N=248 were enrolled in the study, consisting of patients with neuropathy (N=141) and patients without neuropathy (N=107). MTHFR C677T polymorphism was analyzed using polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP) of genomic DNA for genotyping of samples. 1298A/C polymorphism was evaluated using ARMS-PCR. RESULT: There was a significant difference in MTHFR polymorphism between the groups with and without neuropathy. CONCLUSION: Our results suggest that MTHFR 677 variant confer risk for diabetic neuropathy among Iranian patients with type 2 diabetes.
Subject(s)
Diabetes Mellitus, Type 2/genetics , Diabetic Neuropathies/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Polymorphism, Genetic , Case-Control Studies , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/enzymology , Diabetic Neuropathies/diagnosis , Diabetic Neuropathies/enzymology , Female , Gene Frequency , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Iran , Male , Middle Aged , Phenotype , Risk FactorsABSTRACT
In this study, quercetin-loaded zein-based nanofibers were developed using electrospinning technique. The therapeutic effect of these quercetin-loaded nanofibers on neuropathy in streptozotocin- (STZ-) induced diabetes in rats was assessed. Diabetic condition was induced in male Wistar rats by STZ, after which a crush injury of the right sciatic nerve was performed to induce mononeuropathy. Functional recovery was assessed using walking track analysis, measurements of foot withdrawal reflex, nerve conduction velocity, and morphological analysis. The oxidative stress status and the ratio of phosphorylated extracellular recognition kinase (pERK)/extracellular recognition kinase (ERK) expression in the nerve lesion were also assessed in order to elucidate the potential mechanisms involved. Results showed that quercetin-loaded zein-based nanofibers slightly enhanced functional recovery from neuropathy in STZ-diabetic rats. The potential mechanism might partially involve improvements in oxidative stress status and the ratio of pERK/ERK expression in the nerve lesion.
Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Diabetic Neuropathies/drug therapy , Diabetic Neuropathies/physiopathology , Nanofibers/chemistry , Nanotechnology/methods , Quercetin/therapeutic use , Recovery of Function , Animals , Axons/drug effects , Axons/pathology , Diabetes Mellitus, Experimental/enzymology , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Experimental/physiopathology , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/pathology , Disease Models, Animal , Extracellular Signal-Regulated MAP Kinases/metabolism , Male , Nanofibers/ultrastructure , Oxidative Stress/drug effects , Phosphorylation/drug effects , Polymers/chemistry , Quercetin/pharmacology , Rats, Wistar , Recovery of Function/drug effects , Sciatic Nerve/drug effects , Sciatic Nerve/enzymology , Sciatic Nerve/pathology , Sciatic Nerve/physiopathology , Spectroscopy, Fourier Transform Infrared , X-Ray Diffraction , Zein/chemistryABSTRACT
Glutathione peroxidase 1 (Gpx1) is an endogenous antioxidant enzyme. The T allele of the Pro198Leu polymorphism in the Gpx1 (rs1050450, 198C > T) gene is associated with reduced enzyme activity. The aim of this study was to evaluate the association between Pro198Leu polymorphism and risk of diabetic peripheral neuropathy (DPN). We examined 1244 T2DM patients and 730 healthy controls. In the patient group, 33 % had diabetic peripheral neuropathy. All subjects were genotyped for the Gpx1 Pro198Leu polymorphism by polymerase chain reaction and restriction analysis. A significant increase in the T allele and TT genotype frequencies was observed in DPN patients compared to those without DPN (OR 1.55, 95 % CI 1.30-1.85 and 1.89, 95 % CI 1.30-2.74, respectively). The association remained significant after correction for age, disease duration, HbA1c and BMI. When distribution of T allele was compared between DPN+ and DPN- subgroups and controls, OR was 1.54 for DPN+ and 1.00 for DPN- patients. In conclusion, our findings suggest that Gpx1 Pro198Leu genotypes are significantly associated with the risk of diabetic peripheral neuropathy in patients with T2DM. The study provides new clinically relevant information regarding genetic determinants of susceptibility to diabetic neuropathy.
Subject(s)
Diabetes Mellitus, Type 2/genetics , Diabetic Neuropathies/genetics , Glutathione Peroxidase/genetics , Polymorphism, Single Nucleotide , Age of Onset , Aged , Alleles , Cardiovascular Diseases/epidemiology , Case-Control Studies , Comorbidity , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/epidemiology , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/epidemiology , Female , Gene Frequency , Genetic Predisposition to Disease , Genotype , Glutathione Peroxidase/physiology , Glycated Hemoglobin/analysis , Humans , Hyperlipidemias/epidemiology , Male , Middle Aged , Poland/epidemiology , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Glutathione Peroxidase GPX1ABSTRACT
Chronic pain is a major clinical problem that is poorly treated with available therapeutics. Adenosine monophosphate-activated protein kinase (AMPK) has recently emerged as a novel target for the treatment of pain with the exciting potential for disease modification. AMPK activators inhibit signaling pathways that are known to promote changes in the function and phenotype of peripheral nociceptive neurons and promote chronic pain. AMPK activators also reduce the excitability of these cells suggesting that AMPK activators may be efficacious for the treatment of chronic pain disorders, like neuropathic pain, where changes in the excitability of nociceptors is thought to be an underlying cause. In agreement with this, AMPK activators have now been shown to alleviate pain in a broad variety of preclinical pain models indicating that this mechanism might be engaged for the treatment of many types of pain in the clinic. A key feature of the effect of AMPK activators in these models is that they can lead to a long-lasting reversal of pain hypersensitivity even long after treatment cessation, indicative of disease modification. Here, we review the evidence supporting AMPK as a novel pain target pointing out opportunities for further discovery that are likely to have an impact on drug discovery efforts centered around potent and specific allosteric activators of AMPK for chronic pain treatment.
Subject(s)
AMP-Activated Protein Kinases/genetics , Analgesics/therapeutic use , Chronic Pain/drug therapy , Diabetic Neuropathies/drug therapy , Neoplasms/drug therapy , Neuralgia/drug therapy , AMP-Activated Protein Kinases/metabolism , Chronic Pain/enzymology , Chronic Pain/genetics , Chronic Pain/pathology , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/genetics , Diabetic Neuropathies/pathology , Enzyme Activation/drug effects , Gene Expression Regulation , Humans , Inflammation , Ion Channels/genetics , Ion Channels/metabolism , Molecular Targeted Therapy , Morphine/therapeutic use , Neoplasms/enzymology , Neoplasms/genetics , Neoplasms/pathology , Neuralgia/enzymology , Neuralgia/genetics , Neuralgia/pathology , Nociceptors/drug effects , Nociceptors/enzymology , Nociceptors/pathology , Protein Subunits/genetics , Protein Subunits/metabolism , Signal TransductionSubject(s)
rho GTP-Binding Proteins/metabolism , rho-Associated Kinases/metabolism , Diabetes Mellitus/drug therapy , Diabetes Mellitus/enzymology , Diabetic Angiopathies/drug therapy , Diabetic Angiopathies/enzymology , Diabetic Neuropathies/drug therapy , Diabetic Neuropathies/enzymology , Humans , Protein Kinase Inhibitors/pharmacology , rho GTP-Binding Proteins/antagonists & inhibitorsSubject(s)
Diabetic Neuropathies/drug therapy , Aldehyde Reductase/antagonists & inhibitors , Antidepressive Agents/therapeutic use , Complementary Therapies , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/physiopathology , Diabetic Neuropathies/prevention & control , Enzyme Inhibitors/therapeutic use , Humans , Oxidative StressABSTRACT
The 1-deoxysphingolipids (1-deoxySLs) are formed by an alternate substrate usage of the enzyme, serine-palmitoyltransferase, and are devoid of the C1-OH-group present in canonical sphingolipids. Pathologically elevated 1-deoxySL levels are associated with the rare inherited neuropathy, HSAN1, and diabetes type 2 and might contribute to ß cell failure and the diabetic sensory neuropathy. In analogy to canonical sphingolipids, it was assumed that 1-deoxySLs also bear a (4E) double bond, which is normally introduced by sphingolipid delta(4)-desaturase 1. This, however, was never confirmed. We therefore supplemented HEK293 cells with isotope-labeled D3-1-deoxysphinganine and compared the downstream formed D3-1-deoxysphingosine (1-deoxySO) to a commercial synthetic SPH m18:1(4E)(3OH) standard. Both compounds showed the same m/z, but differed in their RPLC retention time and atmospheric pressure chemical ionization in-source fragmentation, suggesting that the two compounds are structural isomers. Using dimethyl disulfide derivatization followed by MS(2) as well as differential-mobility spectrometry combined with ozone-induced dissociation MS, we identified the carbon-carbon double bond in native 1-deoxySO to be located at the (Δ14) position. Comparing the chromatographic behavior of native 1-deoxySO to chemically synthesized SPH m18:1(14Z) and (14E) stereoisomers assigned the native compound to be SPH m18:1(14Z). This indicates that 1-deoxySLs are metabolized differently than canonical sphingolipids.
Subject(s)
Diabetes Mellitus, Type 2/metabolism , Diabetic Neuropathies/metabolism , Hereditary Sensory and Autonomic Neuropathies/metabolism , Sphingosine/analogs & derivatives , Carbon/chemistry , Diabetes Mellitus, Type 2/enzymology , Diabetes Mellitus, Type 2/pathology , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/pathology , HEK293 Cells , Hereditary Sensory and Autonomic Neuropathies/enzymology , Hereditary Sensory and Autonomic Neuropathies/pathology , Humans , Lipids , Oxidoreductases/chemistry , Oxidoreductases/metabolism , Serine C-Palmitoyltransferase/chemistry , Serine C-Palmitoyltransferase/metabolism , Sphingosine/chemistry , Sphingosine/metabolismABSTRACT
Diabetic neuropathy is poorly controlled by classical analgesics and the research of new therapeutic alternatives is indispensable. Our aim is to investigate if treatment with a carbon monoxide-releasing molecule (tricarbonyldichlororuthenium(II) dimer; CORM-2) or an inducible heme oxygenase (HO-1) inducer (cobalt protoporphyrin IX; CoPP) could enhance the antinociceptive effects produced by a δ-opioid receptor (DOR) agonist in mice with painful diabetic neuropathy. In diabetic mice induced by streptozotocin (STZ) injection, the antiallodynic and antihyperalgesic effects produced by the subcutaneous administration of a DOR agonist ([d-Pen(2),d-Pen(5)]-Enkephalin; DPDPE) and the reversion of its effects with the administration of an HO-1 inhibitor (tin protoporphyrin IX; SnPP) were evaluated. Moreover, the antinociceptive effects produced by the intraperitoneal administration of 10mg/kg of CORM-2 or CoPP, alone or combined, with a subanalgesic dose of DPDPE were also assessed. Our results demonstrated that the subcutaneous administration of DPDPE inhibited the mechanical and thermal allodynia as well as the thermal hyperalgesia induced by diabetes in a dose-dependent manner. Moreover, while the antinociceptive effects produced by a low dose of DPDPE were enhanced by CORM-2 or CoPP co-treatments, the inhibitory effects produced by a high dose of DPDPE were completely reversed by the administration of an HO-1 inhibitor, SnPP, indicating the involvement of HO-1 in the antinociceptive effects produced by this DOR agonist during diabetic neuropathic pain in mice. In conclusion, this study shows that the administration of CORM-2 or CoPP combined with a DOR agonist could be an interesting strategy for the treatment of painful diabetic neuropathy.
Subject(s)
Analgesics, Opioid/therapeutic use , Diabetic Neuropathies/drug therapy , Enkephalin, D-Penicillamine (2,5)-/therapeutic use , Heme Oxygenase-1/metabolism , Receptors, Opioid, delta/agonists , Animals , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/physiopathology , Dose-Response Relationship, Drug , Enzyme Induction , Heme Oxygenase-1/antagonists & inhibitors , Hyperalgesia/drug therapy , Hyperalgesia/physiopathology , Injections, Subcutaneous , Male , Mice, Inbred C57BL , Organometallic Compounds/pharmacology , Physical Stimulation , Pyrazines/pharmacology , Pyrroles/pharmacology , RutheniumABSTRACT
CONTEXT: Oxidative stress has been implicated in the progression of pathogenesis in diabetes mellitus and leads to a variety of deformations in the central nervous system. Recent studies have provided several insights on therapeutic uses of resveratrol in diabetic complications. OBJECTIVE: The present study determines if resveratrol ameliorates oxidative stress and molecular changes in the brain frontal cortex of streptozotocin-induced diabetic rats. MATERIALS AND METHODS: Rats were divided into four groups: control, diabetic, resveratrol-treated control, and resveratrol-treated diabetic. After diabetes induction, resveratrol (20 mg/kg) was given intraperitoneally once daily for 4 weeks. In addition to enzymatic activities, gene and protein expression of brain antioxidant enzymes were utilized by qRT-PCR and Western blot, respectively. RESULTS: The results indicated a significant elevation in total oxidant species (1.22-fold) and malonedialdehyde (1.38-fold) contents in diabetic rat brain cortex tissues. In addition, significant augmentation in the activities of catalase (1.38-fold) and superoxide dismutase (3-fold) was witnessed with the gene and protein expression levels reflecting a transcriptional regulation. Resveratrol treatment significantly normalized diabetic malonedialdehyde and oxidized glutathione levels and strengthens the action of all antioxidant enzymes. Recovery of the diabetes-associated changes reflects the reduction of oxidative conditions by resveratrol and reveals the decrease in the requirement for the activation of antioxidant defense systems in the brain tissues of diabetic rats. DISCUSSION AND CONCLUSION: Potent antioxidant and neuroprotective properties of resveratrol against diabetes-induced oxidative damage were demonstrated and the results support the conduct of new studies searching for the molecular mechanism of diabetes-induced changes in brain tissues.
Subject(s)
Antioxidants/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetic Neuropathies/prevention & control , Frontal Lobe/drug effects , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Stilbenes/pharmacology , Streptozocin , Animals , Biomarkers/metabolism , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/enzymology , Diabetes Mellitus, Experimental/genetics , Diabetic Neuropathies/chemically induced , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/genetics , Frontal Lobe/enzymology , Gene Expression Regulation, Enzymologic/drug effects , Glutathione/metabolism , Male , Malondialdehyde/metabolism , Rats, Wistar , ResveratrolABSTRACT
Painful diabetic neuropathy is a common complication of diabetes produced by mechanisms that as yet are incompletely defined. The aim of this study was to investigate the roles of nuclear factor-κB (NF-κB) in the regulation of purinergic receptor P2X ligand-gated ion channel 3 (P2X3R) plasticity in dorsal root ganglion (DRG) neurons of rats with painful diabetes. Here, we showed that hindpaw pain hypersensitivity in streptozocin-induced diabetic rats was attenuated by treatment with purinergic receptor antagonist suramin or A-317491. The expression and function of P2X3Rs was markedly enhanced in hindpaw-innervated DRG neurons in diabetic rats. The CpG (cytosine guanine dinucleotide) island in the p2x3r gene promoter region was significantly demethylated, and the expression of DNA methyltransferase 3b was remarkably downregulated in DRGs in diabetic rats. The binding ability of p65 (an active form of NF-κB) with the p2x3r gene promoter region and p65 expression were enhanced significantly in diabetes. The inhibition of p65 signaling using the NF-κB inhibitor pyrrolidine dithiocarbamate or recombinant lentiviral vectors designated as lentiviral vector-p65 small interfering RNA remarkably suppressed P2X3R activities and attenuated diabetic pain hypersensitivity. Insulin treatment significantly attenuated pain hypersensitivity and suppressed the expression of p65 and P2X3Rs. Our findings suggest that the p2x3r gene promoter DNA demethylation and enhanced interaction with p65 contributes to P2X3R sensitization and diabetic pain hypersensitivity.
Subject(s)
Diabetes Mellitus, Experimental/complications , Diabetic Neuropathies/metabolism , Epigenesis, Genetic , Ganglia, Spinal/metabolism , Neuralgia/metabolism , Receptors, Purinergic P2X3/metabolism , Transcription Factor RelA/metabolism , Animals , CpG Islands/drug effects , DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors , DNA (Cytosine-5-)-Methyltransferases/genetics , DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Methylation/drug effects , Diabetes Mellitus, Experimental/drug therapy , Diabetic Neuropathies/enzymology , Diabetic Neuropathies/prevention & control , Epigenesis, Genetic/drug effects , Female , Ganglia, Spinal/drug effects , Ganglia, Spinal/enzymology , Gene Expression Regulation/drug effects , Hindlimb , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neuralgia/complications , Neuralgia/prevention & control , Neurons/drug effects , Neurons/enzymology , Neurons/metabolism , Promoter Regions, Genetic/drug effects , Purinergic P2X Receptor Antagonists/therapeutic use , RNA Interference , Rats, Sprague-Dawley , Receptors, Purinergic P2X3/chemistry , Receptors, Purinergic P2X3/genetics , Transcription Factor RelA/agonists , Transcription Factor RelA/antagonists & inhibitors , Transcription Factor RelA/genetics , DNA Methyltransferase 3BABSTRACT
Painful diabetic neuropathy is a common complication of diabetes mellitus, which often makes the patients suffer from severe hyperalgesia and allodynia. Thus far, the treatment of painful diabetic neuropathy remains unsatisfactory. Metformin, which is the first-line drug for type-2 diabetes, has been proved to attenuate hyperexcitability in sensory neurons linked to chemotherapy-induced neuropathic pain, highlighting its potential in alleviating pain related with painful diabetic neuropathy. The present study was designed to investigate the potential beneficial effect of metformin on hyperalgesia and allodynia in diabetic rats. The mechanical sensitivity, heat nociception, and cold allodynia were examined. The levels of malondialdehyde, superoxide dismutase, and advanced glycation end-products in the blood were measured. The expression of adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and AMPK target genes were examined in the sciatic nerves of the animals. It was found that metformin was capable of attenuating diabetes-induced mechanical hyperalgesia, heat hyperalgesia and cold allodynia. In addition, metformin was capable of decreasing malondialdehyde and glycation end-products levels in blood, as well as increasing superoxide dismutas activity, indicating the inhibitory effect of metformin against diabetes-induced oxidative stress. Further studies showed that metformin could activate AMPK and increase the AMPK target genes in sciatic nerves in diabetic rats. In conclusion, metformin is able to attenuate diabetes-induced hyperalgesia and allodynia, which might be associated its anti-oxidative effect through AMPK pathway. Metformin might be used as an effective drug, especially with fewer side effects, for abnormal sensation in painful diabetic neuropathy.